BioSpace News Archive

Paula Mabee, the Nolop Distinguished Professor in the Department of Biology at the University of South Dakota, has been selected as the Chief Scientist and Observatory Director of the National Ecological Observatory Network (NEON).

Eye tracking startup transforms mobile devices into assistive technology tools, making eye-powered communication more accessible to millions in need

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a progress update on FUROSCIX® including progress on both the drug and device validation, and the successful completion of the human factors program.

Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, announced the presentation of preclinical data supporting development of its lead ImmunoTAC™ candidate, SBT6050, at the San Antonio Breast Cancer Symposium.

Augury, a leading AI-based machine health solution provider, today announced an investment by Qualcomm Ventures LLC, a subsidiary of Qualcomm Incorporated, a global leader in 5G technologies, to accelerate the transformation of the industrial sector.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from study SEP361-202 which evaluated the long-term safety and effectiveness of SEP-363856, a novel non-dopamine 2 (D2) agent under investigation for the treatment of patients with schizophrenia.

Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has secured its first order for the use of OxC-beta™ Livestock in Malaysia

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announced top-line results from the European Phase 3 study, “FM57” of its lead product candidate, MED2005, for the treatment of erectile dysfunction (ED).

Ensysce Biosciences Inc., a clinical phase company with innovative solutions for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, today announced the appointment of Andrew K. Benton to its Board of Directors

Akili Interactive (“Akili” or “Company”), today announced results of its randomized, controlled study of digital therapeutic AKL-T03 as a treatment for cognitive impairments adjunct to anti-depressant medication in adults with MDD.